Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co | Buenos Aires | Salute | Prodotti farmaceutici | 809,26 Bln ARS | 112,8x | 8,72 | 19.500 ARS | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
UnitedHealth Group | Buenos Aires | Salute | Fornitori e servizi sanitari | 510,82 Bln ARS | 36,4x | -1,21 | 20.425 ARS | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Johnson Johnson DRC | Buenos Aires | Salute | Prodotti farmaceutici | 388,84 Bln ARS | 27x | 1.600 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Johnson & Johnson DRC | Buenos Aires | Salute | Prodotti farmaceutici | 388,77 Bln ARS | 27x | 0,11 | 13.100 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Johnson & Johnson | Buenos Aires | Salute | Prodotti farmaceutici | 378,84 Bln ARS | 10,4x | 0,31 | 815 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Abbvie | Buenos Aires | Salute | Prodotti farmaceutici | 326,51 Bln ARS | 63x | -1,68 | 22.450 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Merck & Co DRC | Buenos Aires | Salute | Prodotti farmaceutici | 270,88 Bln ARS | 20,1x | 0,06 | 25.900 ARS | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
AstraZeneca PLC | Buenos Aires | Salute | Prodotti farmaceutici | 236,66 Bln ARS | 37,4x | 8,67 | 46.500 ARS | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Novartis DRC | Buenos Aires | Salute | Prodotti farmaceutici | 231,92 Bln ARS | 14,8x | 0,2 | 34.700 ARS | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Thermo Fisher Scientific | Buenos Aires | Salute | Attrezzature e forniture medicali | 225,09 Bln ARS | 37,1x | 3,6 | 32.475 ARS | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Abbott Laboratories | Buenos Aires | Salute | Attrezzature e forniture medicali | 203,10 Bln ARS | 36x | 4,38 | 35.375 ARS | 0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Amgen AR | Buenos Aires | Salute | Prodotti farmaceutici | 169,07 Bln ARS | 55,1x | -0,92 | 12.850 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Pfizer DRC | Buenos Aires | Salute | Prodotti farmaceutici | 162,23 Bln ARS | -63,5x | 0,57 | 8.680 ARS | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Medtronic | Buenos Aires | Salute | Attrezzature e forniture medicali | 114,31 Bln ARS | 30,4x | 3,05 | 27.025 ARS | 1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Gilead Sciences | Buenos Aires | Salute | Prodotti farmaceutici | 105,91 Bln ARS | 103x | -1,24 | 26.000 ARS | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bristol-Myers Squibb DRC | Buenos Aires | Salute | Prodotti farmaceutici | 105,60 Bln ARS | -16,5x | 0,09 | 21.025 ARS | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
GSK plc DRC | Buenos Aires | Salute | Prodotti farmaceutici | 76,74 Bln ARS | 14,8x | -0,2 | 11.475 ARS | -1,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Koninklijke Philips DRC | Buenos Aires | Salute | Attrezzature e forniture medicali | 29,35 Bln ARS | -64,2x | -0,63 | 7.620 ARS | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Biogen AR | Buenos Aires | Salute | Prodotti farmaceutici | 27,17 Bln ARS | 23,9x | -0,42 | 17.475 ARS | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cardinal Health | Buenos Aires | Salute | Prodotti farmaceutici | 26,52 Bln ARS | 32,1x | 0,18 | 44.725 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Laboratorios Richmond | Buenos Aires | Salute | Prodotti farmaceutici | 75,91 Mrd ARS | 21,4x | 0,12 | 940 ARS | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Inst rosembusc | Buenos Aires | Salute | Prodotti farmaceutici | 3,83 Mrd ARS | 3,8x | 0,01 | 90 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |